Be the first to review this item
Cavinton (Vinpocetinum, Vinpocetine) - a drug that improves cerebral blood flow, cerebral metabolism and blood rheology.
It has cerebroprotective effect. It reduces the severity of damaging cytotoxic reactions caused by stimulating amino acids; It inhibits the functional activity of the cell as a transmembrane sodium and calcium channels as well as NMDA and AMPA receptors. Potentiate the neuroprotective effect of adenosine. It stimulates the brain metabolism, enhances the absorption and assimilation of the brain glucose and oxygen. It stimulates glucose transport across the BBB, shifts the metabolism of glucose in the energetically more favorable aerobic. Selectively inhibits Ca2 + -kalmodulin cGMP-dependent phosphodiesterase, increases the concentration of cAMP and cGMP in brain tissues, as well as the concentration of ATP and ATP / AMP ratio. It stimulates cerebral metabolism of noradrenaline and serotonin and stimulates the ascending noradrenergic system, has an antioxidant effect.
The drug selectively enhances cerebral blood flow: increases cerebral fraction of cardiac output; reduces the resistance of cerebral vessels, without affecting the general circulatory parameters (blood pressure, cardiac output, heart rate, PR).
It does not cause the phenomenon of "steal"; Conversely, when it is used primarily reinforced blood flow of ischemic but still viable areas with low perfusion - phenomenon "reverse steal".
Improves tolerance of hypoxia of the brain cells, facilitating oxygen transport to the tissues due to reduced affinity to his red blood cells.
The drug improves cerebral microcirculation, inhibits platelet aggregation, reduces pathologically increased blood viscosity, increases the deformability of red blood cells and blocks the absorption of adenosine.
In neurology - acute and chronic cerebrovascular insufficiency (transient ischemia, progressing stroke, post-stroke, vascular dementia, atherosclerosis, cerebral vascular, traumatic and hypertensive encephalopathy, vertebrobasilar-basilar insufficiency); mental and neurological disorders in patients with cerebrovascular insufficiency (including memory impairment, dizziness, headache, aphasia, apraxia, motor disorders).
In ophthalmology - vascular eye diseases (arteriosclerosis, vasospasm choroid and retina, degenerative diseases of the choroid, retina or macula, arterial and venous thrombosis or embolism, secondary glaucoma).
In ENT practice - hearing loss (vascular, toxic or age genesis), Meniere's disease, kohleovestibulyarny neuritis, tinnitus, vertigo (labyrinthine origin); vasovegetative climacteric syndrome.
Pregnancy; lactation; severe heart failure and heart rhythm disturbances; hypersensitivity to vinpocetine or other components of the preparation.
Cavintonum not have hepato- and nephrotoxic, so when administering the drug to patients with diseases of the liver and kidneys correct dosing regimen is required.
In case of intolerance to lactose should note that each tablet contains 83 mg of lactose.
Use in Pediatrics
Do not appoint a drug to children under the age of 18 years due to lack of experience with Cavinton in these patients.
Since the cardiovascular system: possible exacerbations of existing arrhythmias.
From the digestive system: nausea, heartburn, dry mouth.
CNS: headache, dizziness, sleep disturbance, fatigue.
Allergic reactions: skin rash, urticaria.
Skin reactions: flushing of the skin.
The course of treatment and the dosage determined by the treating physician.
In most cases, take 1 tablet (10 mg) 3 times a day.
Cavinton should be taken after meals.
The course is from 1 to 8 months, on average - 4.3 months. In the case of withdrawal of the drug dose Cavinton reduce for 2-3 days.
Important notice- the outer box design may vary before prior notice!